StreetInsider.com News Articles

Form 4 GILEAD SCIENCES, INC. For: Jun 01 Filed by: O'Day Daniel Patrick

Tue, 02 Jun 2026 18:04:00 -0400

si-local-file:///var/storage/secattach/20260602/26593610.html

Form 4 GILEAD SCIENCES, INC. For: Jun 01 Filed by: O'Day Daniel Patrick

Tue, 02 Jun 2026 18:04:00 -0400

si-local-file:///var/storage/secattach/20260602/26593610.html

GILD reports positive results for Livdelzi in PBC patients with mild ALP elevation

Tue, 02 Jun 2026 08:30:46 -0400

Gilead Sciences Inc. (NASDAQ: GILD) announced that its Phase 3 IDEAL trial of Livdelzi (seladelpar) met its primary endpoint in patients with primary biliary cholangitis who had alkaline phosphatase levels between normal and 1.67 times the upper limit of normal.

The 52-week study showed statistically significant composite ALP normalization compared to placebo in patients with inadequately controlled disease despite treatment with ursodeoxycholic acid or those intolerant to UDCA. The primary endpoint was defined as ALP levels at or below 1.0 times the upper limit of normal plus at least a 15% decrease from baseline.

The trial enrolled 96 adults aged 18-75 years

GILD reports positive results for Livdelzi in PBC patients with mild ALP elevation

Tue, 02 Jun 2026 08:30:46 -0400

The trial enrolled 96 adults aged 18-75 years

Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)

Tue, 02 Jun 2026 08:30:00 -0400

– IDEAL Evaluated Livdelzi in People Living with PBC with Elevated ALP Levels (1-1.67xULN) on or Intolerant to UDCA –

– 52-Week Results Demonstrate High and Sustained ALP Normalization and Generally Well-Tolerated Safety Profile –

– Findings Add to Growing Evidence Supporting ALP Normalization as an Achievable Treatment Goal in PBC –

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive results from a Phase 3 study in people with primary biliary cholangitis (PBC), showing that treatment with Livdelzi® (seladelpar) led to significantly more patients achieving normalization of alkaline phosphatase (ALP), a key liver

Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)

Tue, 02 Jun 2026 08:30:00 -0400

– IDEAL Evaluated Livdelzi in People Living with PBC with Elevated ALP Levels (1-1.67xULN) on or Intolerant to UDCA –

– 52-Week Results Demonstrate High and Sustained ALP Normalization and Generally Well-Tolerated Safety Profile –

– Findings Add to Growing Evidence Supporting ALP Normalization as an Achievable Treatment Goal in PBC –

Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)

Tue, 02 Jun 2026 08:30:00 -0400

– IDEAL Evaluated Livdelzi in People Living with PBC with Elevated ALP Levels (1-1.67xULN) on or Intolerant to UDCA –

– 52-Week Results Demonstrate High and Sustained ALP Normalization and Generally Well-Tolerated Safety Profile –

– Findings Add to Growing Evidence Supporting ALP Normalization as an Achievable Treatment Goal in PBC –

Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)

Tue, 02 Jun 2026 08:30:00 -0400

– IDEAL Evaluated Livdelzi in People Living with PBC with Elevated ALP Levels (1-1.67xULN) on or Intolerant to UDCA –

– 52-Week Results Demonstrate High and Sustained ALP Normalization and Generally Well-Tolerated Safety Profile –

– Findings Add to Growing Evidence Supporting ALP Normalization as an Achievable Treatment Goal in PBC –

Form 144 GILEAD SCIENCES, INC. Filed by: O'Day Daniel Patrick

Mon, 01 Jun 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260601/26584586.html

Form 144 GILEAD SCIENCES, INC. Filed by: O'Day Daniel Patrick

Mon, 01 Jun 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260601/26584586.html

RBC Capital Reiterates Sector Perform Rating on Gilead Sciences (GILD)

Mon, 01 Jun 2026 07:47:16 -0400

RBC Capital analyst Brian Abrahams reiterated a Sector Perform rating and $122.00 price target on Gilead Sciences (NASDAQ: GILD).

The analyst commented: "Expect Biktarvy Resilience, But GILD May Be A Victim Of Their Own Success; We hosted a panel with two top KOLs discussing current and next-gen HIV/PrEP options, particularly timely with expected nearterm progress/data with several competitive regimens. KOLs sound more enthusiastic than expected about potential of GILD's late-stage bic/len regimen (though more incremental market expansion rather than life cycle conversion), expressed confidence yearly IM Yeztugo will improve profile and potentially expand LT PrEP opportunity, and expect resilient Biktarvy use

Gilead's Livdelzi shows sustained liver marker improvement in PBC study

Wed, 27 May 2026 02:00:41 -0400

Gilead Sciences Inc. (NASDAQ: GILD) reported interim data from its Phase 3 ASSURE study showing that Livdelzi (seladelpar) achieved sustained normalization of alkaline phosphatase (ALP) levels in patients with primary biliary cholangitis who had mildly elevated baseline levels.

In a post hoc analysis of 50 participants with baseline ALP levels between 1.0 and 1.67 times the upper limit of normal, 83% achieved composite ALP normalization at 12 months and 74% maintained this response at 24 months. The composite endpoint was defined as ALP levels at or below the upper limit of normal with at least a 15% reduction from baseline.

The ASSURE

Gilead's Livdelzi shows sustained liver marker improvement in PBC study

Wed, 27 May 2026 02:00:41 -0400

The ASSURE

Gilead's Livdelzi shows sustained liver marker improvement in PBC study

Wed, 27 May 2026 02:00:41 -0400

The ASSURE

Gilead's Livdelzi shows sustained liver marker improvement in PBC study

Wed, 27 May 2026 02:00:41 -0400

The ASSURE

Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)

Wed, 27 May 2026 02:00:00 -0400